GTx, Inc. (GTXI) Provides Corporate Update And Reports Third Quarter 2013 Financial Results
11/12/2013 10:21:54 AM
GTx, Inc. (Nasdaq: GTXI) today provided a Company update and reported financial results for the third quarter of 2013. The Company summarized additional analyses it has undertaken of the POWER1 and POWER2 clinical trials evaluating enobosarm 3 mg for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer (NSCLC). Using longitudinal continuous variable analyses, which was the statistical analysis pre-specified by the Company for submission of its data to the European regulatory authorities, enobosarm 3 mg demonstrated significant improvement in stair climb power, compared to placebo, in the POWER1 (platinum plus taxane) trial.
Help employers find you! Check out all the jobs and post your resume.
comments powered by